ライフサイエンスコーパス: mammographic

1 ications, and masses) was evaluated with the mammographic accreditation ACR phantom.

2 --consistent with mammographic data; and the mammographic and (post-operative) pathologic sizes are l

3 ateral breast cancer and no abnormalities on mammographic and clinical examination of the contralater

4 radiologists with expertise in interpreting mammographic and CT findings independently reviewed the

5 Imaging Reporting and Data System (BI-RADS) mammographic and magnetic resonance (MR) imaging feature

6 agreement between BPE levels on CE spectral mammographic and MR images and among readers, weighted k

7 aders independently rated BPE on CE spectral mammographic and MR images with the ordinal scale: minim

8 ween readers for BPE detected on CE spectral mammographic and MR images.

9 Mammographic and MR imaging features were retrospectivel

10 ation carriers, incorporating the effects of mammographic and MRI screening was used.

11 A reader blinded to mammographic and pathologic findings assessed diagnosis

12 ifications, or other), digital machine type, mammographic and pathologic size and diagnosis, existenc

13 ant, were recruited from 21 sites to undergo mammographic and physician-performed ultrasonographic ex

14 Results showed that combining mammographic and sonographic descriptors in a CAD model

15 ded diagnosis (CAD) models that include both mammographic and sonographic descriptors.

16 Mammographic and sonographic examinations were performed

17 ediolateral oblique and craniocaudal digital mammographic and tomosynthesis images of both breasts we

18 f malignancy were determined after biopsy or mammographic and US follow-up at a minimum of 11 months.

19 Clinical history; histopathologic, mammographic, and breast sonographic findings; and HER2

20 ancement kinetic characteristics varied with mammographic appearance but not with nuclear grade.

21 ages with the nuclear grade and conventional mammographic appearance of these lesions.

22 The rate of false-positive mammographic assessments was also lower for women who un

23 hat did not reveal cancer and false-positive mammographic assessments.

24 reading to occur only in women with a denser mammographic background pattern (P = .02).

25 Mammographic breast cancer detection in the CEE group wa

26 Percent mammographic breast density (PMD) is a strong heritable

27 n requiring radiology facilities to disclose mammographic breast density information to women, often

28 Results Mammographic breast density was inversely associated wit

29 Limitation: Quantitative measures of mammographic breast density were not available for compa

30 hysical activity levels, and diet with adult mammographic breast density, a strong risk factor for br

31 erogeneity=0.01) and is also associated with mammographic breast density, a strong risk factor for br

32 Measurements: Mammographic breast density, as clinically recorded usin

33 Conclusion The BI-RADS features of mammographic breast density, calcification morphology, m

34 50-64 years who were invited to and attended mammographic breast screening from April 1, 2003, to Mar

35 n ADH involves fewer than three foci and all mammographic calcifications have been removed, because t

36 Needle biopsy was performed because of mammographic calcifications in 215 of the 276 lesions (7

37 ates were similar, regardless of whether all mammographic calcifications were removed (seven [17%] of

38 xteen radiologists independently reviewed 60 mammographic cases: 20 cases with cancer and 40 cases wi

39 umour grows 7-10mm per year--consistent with mammographic data; and the mammographic and (post-operat

40 Mammographic database review (1994-2003) revealed core b

41 investigated the concurrent associations of mammographic dense and nondense areas, body mass index (

42 ercentage density (P for trend = .0001), and mammographic dense area (P for trend = .0052), with incr

43 erved a statistically significant decline in mammographic dense area (P for trend = .036) with increa

44 a non-statistically significant increase in mammographic dense area and percentage density with incr

45 Mammographic dense area was positively associated with r

46 Age-adjusted percent mammographic densities in Afro-Caribbeans and South Asia

47 as tailored to lifetime risk (Gail test) and mammographic density (according to Breast Imaging Report

48 countries in the International Consortium on Mammographic Density (ICMD).

49 Mammographic density (MD) is one of the strongest breast

50 ted 10-year breast cancer risk score (TCRS), mammographic density (MD), and a 77-single nucleotide po

51 colony organization, at the maximum level of mammographic density (MD), are investigated.

52 Increased mammographic density (MD), the proportion of dense tissu

53 aracteristics (n = 4,091), risk factors, and mammographic density (n = 1,957) were included.

54 = 0.36) became positive after adjustment for mammographic density (odds ratio = 1.28, 95% confidence

55 Percent mammographic density (PMD) adjusted for age and body mas

56 Percent mammographic density adjusted for age and body mass inde

57 High-percent mammographic density adjusted for age and body mass inde

58 We studied the change in mammographic density after a breast cancer diagnosis and

59 Previous studies have linked reductions in mammographic density after a breast cancer diagnosis to

60 A decrease in mammographic density after breast cancer diagnosis appea

61 treatment is associated with a reduction in mammographic density and an improved survival.

62 r evidence of a shared genetic basis between mammographic density and breast cancer and illustrate th

63 uate the strength of the association between mammographic density and breast cancer risk using differ

64 To maximize statistical power in studies of mammographic density and breast cancer, it is advantageo

65 ations of plasma leptin and adiponectin with mammographic density and disease status and assessed the

66 onectin levels were directly associated with mammographic density and HDL cholesterol and negatively

67 Mammographic density and lobular involution are both sig

68 requiring that women be informed about their mammographic density and related adjunct imaging.

69 e genome-wide association studies of percent mammographic density and report an association with rs10

70 At lower levels of MDA, mammographic density and telomere length were inversely

71 s evidence of a J-shaped association between mammographic density and telomere length.

72 n ERBB2 (HER2(+) or HER2(-)) tumor subtypes, mammographic density and tumor grade.

73 Ethnic differences in mammographic density are consistent with those for breas

74 e results provide new insights into how high mammographic density arises and why it is associated wit

75 ingdom population-based multiethnic study of mammographic density at ages 50-64 years in 645 women.

76 The percent mammographic density at the first available mammogram wa

77 ated with a weaker annual decline in percent mammographic density by 0.09% (standard error = 0.03; P

78 We measured mammographic density by a computer assisted method and b

79 tatistically significant association between mammographic density change and survival.

80 Conversely, mammographic density does not appear to explain the inve

81 However, the extent to which change in mammographic density during adjuvant tamoxifen therapy c

82 Interval breast cancers in women with low mammographic density have the most aggressive phenotype.

83 hysical activity, body mass index (BMI), and mammographic density in a racially/ethnically diverse po

84 We examined the effect of CEE alone on mammographic density in a subsample of the Women's Healt

85 conjugated equine estrogens (CEEs) alone on mammographic density in diverse racial/ethnic population

86 st prominent difference between low and high mammographic density in healthy breast tissue by PARADIG

87 y measured circulating carotenoid levels and mammographic density in the Nurses' Health Study.

88 High mammographic density is a strong breast cancer risk fact

89 Mammographic density is a strong risk factor for breast

90 Extensive mammographic density is a strong risk factor for breast

91 Increased mammographic density is associated with increased breast

92 In this study, mammographic density is measured by using a fully automa

93 Mammographic density is one of the strongest predictors

94 In this study we examined whether mammographic density is related to blood telomere length

95 investigated whether the level of decline in mammographic density is related to breast cancer risk us

96 Mammographic density is strongly associated with breast

97 n may be an important genetic determinant of mammographic density measure that predicts breast cancer

98 y variants were associated with at least one mammographic density measure.

99 Mammographic density measurements are associated with ri

100 Mammographic density measures adjusted for age and body

101 They had a total of 6,317 mammographic density measures available from the first 5

102 ociated with both breast cancer risk and the mammographic density measures.

103 Conclusion Mammographic density on FFDM images was positively assoc

104 omere length was not associated with percent mammographic density or dense area, before or after adju

105 ome-wide association studies (GWAS) of three mammographic density phenotypes: dense area, non-dense a

106 dentify etiologic pathways implicated in how mammographic density predicts breast cancer risk.

107 Mammographic density reflects the amount of stromal and

108 e clinical significance of the CEE effect on mammographic density remains to be determined.

109 However, mammographic density significantly modified the associat

110 spective data from the Early Determinants of Mammographic Density Study (n = 1,108; 1959-2008), we ex

111 st but statistically significant increase in mammographic density that is sustained over at least a 2

112 udy, we show that epithelial cells from high mammographic density tissues have more DNA damage signal

113 s seen in desmoplastic and disease-free high mammographic density tissues.

114 risk for developing cancer, especially high mammographic density tissues.

115 onse compared with epithelial cells from low mammographic density tissues.

116 ome-wide association study (GWAS) of percent mammographic density to identify novel genetic loci asso

117 use, and body mass index predict changes in mammographic density trends during adult life.

118 Interreader agreements for the mammographic density types and CT density grades were de

119 igher for the CT density grades than for the mammographic density types, with 0.79 (95% confidence in

120 0, a single reader reassessed all images for mammographic density using Cumulus software (Sunnybrook

121 .6 years, the mean annual decline in percent mammographic density was 1.1% (standard deviation = 0.1)

122 Change in mammographic density was calculated as percentage change

123 Mammographic density was estimated as the four-category

124 Mammographic density was measured by using a computer-as

125 Mammographic density was measured by using an automated

126 s central), amount of FGT at MR imaging, and mammographic density were assessed on index images.

127 We examined whether age-related changes in mammographic density were different for 533 cases and 1,

128 ed breast cancer after adjusting for age and mammographic density were family history of breast cance

129 BPE pattern, MR imaging amount of FGT, and mammographic density were not significantly different be

130 tive would have a greater decline in percent mammographic density with age, compared with less physic

131 se results and to examine the association of mammographic density with age-related chronic disease an

132 The associations of mammographic density with breast cancer and the model fi

133 val breast cancers in dense breasts (> 40.9% mammographic density) were less aggressive than interval

134 breast cancers in nondense breasts (</= 20% mammographic density) were significantly more likely to

135 The associations are independent of BMI, mammographic density, and treatment.

136 larly, among women in the highest tertile of mammographic density, high levels of circulating alpha-c

137 somatotype at age 18, benign breast disease, mammographic density, polygenic risk score, family histo

138 Percent mammographic density, the proportion of dense breast tis

139 Among women in the highest tertile of mammographic density, total carotenoids were associated

140 le predictors of breast cancer risk, but few mammographic density-associated genetic variants have be

141 signaling has been associated with increased mammographic density.

142 .27 to 0.93) compared with women with stable mammographic density.

143 be partially due to negative confounding by mammographic density.

144 st cancer risk remained after adjustment for mammographic density.

145 n inverse association between involution and mammographic density.

146 er through a mechanism that includes reduced mammographic density.

147 otect against breast cancer is by decreasing mammographic density.

148 cer risk, particularly among women with high mammographic density.

149 isted thresholding method to measure percent mammographic density.

150 carotenoids and breast cancer risk varies by mammographic density.

151 breast cancer risk through its influence on mammographic density.

152 and breast cancer risk among women with low mammographic density.

153 ng carotenoids are inversely associated with mammographic density.

154 last four factors were associated with lower mammographic density.

155 women in the United Kingdom are reflected in mammographic density.

156 a reasonable intervention approach to reduce mammographic density.

157 ere length and MDA in their association with mammographic density.

158 orresponds to the collagen component at high mammographic density.

159 breast cancer risk is not fully explained by mammographic density.

160 he SNP most strongly associated with percent mammographic density.

161 associated with both breast cancer risk and mammographic density.

162 d by highest and lowest quartiles of percent mammographic density.

163 For mammographic descriptors, moderate agreement was obtaine

164 DMIST cancers were evaluated with respect to mammographic detection method (digital vs film vs both v

165 eafter, unless otherwise indicated, a yearly mammographic evaluation should be performed.

166 eafter, unless otherwise indicated, a yearly mammographic evaluation should be performed.

167 Even after careful clinical and mammographic evaluation, cancer is found in the contrala

168 based on a cohort of women who had received mammographic evaluations.

169 omen who arrived for their routine screening mammographic examination from November 2004 to March 200

170 ons were reported on the basis of the second mammographic examination regardless of acquisition metho

171 spondents undergoing their initial screening mammographic examination, women who had undergone at lea

172 eral breast cancers were diagnosed in 10 715 mammographic examinations (2.5 cancers per 1000 examinat

173 Diagnostic and screening tomosynthesis mammographic examinations (n = 175; cranial caudal and m

174 nts among 83,511 women who underwent 314,185 mammographic examinations from January 1, 1985, to Febru

175 A retrospective review of the screening mammographic examinations identified 42.9% (39 of 91) of

176 aminations) compared with 16 cancers in 6916 mammographic examinations in the RTAS group (2.3 cancers

177 d older who underwent at least two screening mammographic examinations less than 36 months apart betw

178 ase was done to identify bilateral screening mammographic examinations obtained from January 1, 1999,

179 st-BCT protocol, which recommends semiannual mammographic examinations of the ipsilateral breast for

180 Results There were 8818 MR and 6245 mammographic examinations performed in 2463 women.

181 m 2009 to 2014, during which 108 276 digital mammographic examinations were performed (50 062 before

182 MR imaging examinations and 26 866 screening mammographic examinations were performed.

183 Two hundred mammographic examinations were selected from examination

184 who underwent 10,641 screening or diagnostic mammographic examinations with abnormal results between

185 e (91% vs 86%; P = .03) and those with total mammographic experience of fewer than 80 000 cases (88%

186 The size and predominant mammographic feature of the cancer were recorded, as was

187 The mammographic features (masses, architectural distortions

188 with false-positive findings and in whom the mammographic features changed over time had a highly inc

189 Previous mammographic features might yield useful information for

190 The mammographic features of 131 NLCs with reduced E-cadheri

191 nsity have relied on one assessment, yet the mammographic features of the breast that constitute brea

192 Women in whom mammographic features showed changes in subsequent false

193 ancers missed at FFDM tend to have different mammographic features than those missed at SFM.

194 reduced E-cadherin expression appear to have mammographic features that make them difficult to detect

195 Cancers were classified as missed or true, mammographic features were described, percentages were c

196 ts according to radiologic classification of mammographic features.

197 rics of breast density on full-field digital mammographic (FFDM) images as predictors of future breas

198 Lesion location, mammographic finding, core number, or needle type were n

199 s (age, family history, and hormone use) and mammographic findings (described using the established l

200 rate was 0% for all US findings and for all mammographic findings except pure clustered microcalcifi

201 We imaged 4 women with mammographic findings highly suggestive of breast cancer

202 For mammographic findings other than pure clustered microcal

203 and use of hormone replacement therapy) and mammographic findings recorded in the Breast Imaging Rep

204 board-approved study, 205 patients with 216 mammographic findings suspicious for cancer were schedul

205 PPV of mammographic findings was evaluated in a prospective coh

206 Mammographic findings were matched with a state cancer r

207 MR and mammographic findings were reviewed.

208 in five additional patients on the basis of mammographic findings, and malignancy was detected in th

209 Excisional or mammographic follow-up (>or=2 years) findings were avail

210 Mammographic follow-up in the remaining seven lesions re

211 nfrequently (3%) associated with malignancy; mammographic follow-up is reasonable.

212 early breast clinical examination and yearly mammographic follow-up to detect an eventual cancer in i

213 All 275 women underwent one mammographic follow-up, 205 (74.5%) underwent a second m

214 ic follow-up, 205 (74.5%) underwent a second mammographic follow-up, and 147 (53.5%) underwent a thir

215 At repeat biopsy or mammographic follow-up, outcome was evaluated in patient

216 Excluding initial mammographic follow-up, there were 8234 examinations.

217 follow-up, and 147 (53.5%) underwent a third mammographic follow-up.

218 ay be important, as standard two-dimensional mammographic images are increasingly being replaced by s

219 tissues by volume when two-dimensional x-ray mammographic images are used.

220 c and enhancement imaging features on MR and mammographic images in screening and prior examinations.

221 nal treatment, breast density on CE spectral mammographic images, and amount of fibroglandular tissue

222 The primary HIPAA-compliant Digital Mammographic Imaging Screening Trial (DMIST) was approve

223 demographic information, clinical findings, mammographic interpretation, and biopsy results.

224 esian networks may help radiologists improve mammographic interpretation.

225 or in reducing recall recommendations during mammographic interpretation.

226 method (digital vs film vs both vs neither), mammographic lesion type (mass, calcifications, or other

227 Simulated mammographic lesions that mimicked benign and malignant

228 15 of the 276 lesions (77.9%) and because of mammographic masses in 35 (12.7%).

229 arriers (MR imaging median size = 12.5 mm vs mammographic median size = 6 mm; P = .067); the differen

230 agnostic criterion to rule out malignancy in mammographic microcalcifications at breast MR imaging.

231 hanced MR imaging was used for assessment of mammographic microcalcifications that were assigned Brea

232 r diagnosis of malignancy in BI-RADS 3 and 5 mammographic microcalcifications, but can be considered

233 cations, but can be considered for BI-RADS 4 mammographic microcalcifications.

234 cal mechanisms regulating the role played by mammographic nondense area and body fat on breast cancer

235 Mammographic nondense area was inversely associated with

236 Mammographic PD was estimated with software.

237 Use of CEE resulted in mean increase in mammographic percent density of 1.6 percentage points (9

238 The effect of CEE on mammographic percent density was determined over 1 and 2

239 Mammographic percent density was estimated using a compu

240 r for breast cancer, is also associated with mammographic percent density.

241 Community screening mammographic performance measurements of cancer outcomes

242 by using about 22% of the dose for a single mammographic projection.

243 Number of mammographic readings per year was positively related wi

244 For individuals with more than 5000 mammographic readings per year, JAFROC values were posit

245 factor in individuals with a high volume of mammographic readings.

246 ogists with annual volumes of less than 1000 mammographic readings.

247 A retrospective search of the institutional mammographic results database was done to identify bilat

248 ing reduces the occurrence of false-positive mammographic results.

249 than white women to have received inadequate mammographic screening (relative risk, 1.2 [95% CI, 1.2

250 comfort may improve the likelihood of future mammographic screening and early detection of breast can

251 Widespread mammographic screening and effective systemic therapies

252 orted that their cancer had been detected by mammographic screening and half that they or their clini

253 Digital mammographic screening beginning at ages 25, 30, 35, and

254 Adding annual MR imaging to annual mammographic screening cost $69125 for each additional Q

255 data were linked to prescription refill and mammographic screening databases.

256 ars who underwent 789 481 full-field digital mammographic screening examinations during 2004-2012 was

257 mors account for a substantial proportion of mammographic screening failure.

258 compared the effect of invitation to annual mammographic screening from age 40 years with commenceme

259 tablish the clinical effectiveness of annual mammographic screening in women younger than 50 years wi

260 Mammographic screening is impractical in most of the wor

261 te all-clear result, participating in annual mammographic screening is psychologically beneficial.

262 st cancer and all breast cancers in the U.S. mammographic screening population, with screening of wom

263 the four authors of this article each set up mammographic screening programs and independently develo

264 Prompt annual attendance for mammographic screening reduces the occurrence of false-p

265 an women are less likely to receive adequate mammographic screening than white women, which may expla

266 The widespread use of mammographic screening will increase the number of patie

267 without CAD; the second, of women undergoing mammographic screening with CAD; and the third, of women

268 first group was composed of women undergoing mammographic screening without CAD; the second, of women

269 Age-specific effects of mammographic screening, and the timing of such effects,

270 (n = 102) was more likely to be detected on mammographic screening, had smaller median size, and les

271 With mammographic screening, the frequency of diagnosis of st

272 In regions of the world that lack mammographic screening, the routine use of clinical brea

273 cer and cancer diagnosis are associated with mammographic screening.

274 ng a period prior to the onset of widespread mammographic screening.

275 Microcalcifications are an early mammographic sign of breast cancer and a target for ster

276 Microcalcifications are an early mammographic sign of breast cancer and frequent target f

277 Patient age, location and mammographic size of the lesion, type of lesion, and bre

278 ormance between the systems, 192 consecutive mammographic studies (182 unifocal, six multifocal, and

279 A total of 1 333 541 mammographic studies (hereafter called "mammograms") ove

280 There were 2 580 151 screening mammographic studies from 1 117 390 women (age range, <3

281 logic size and diagnosis, existence of prior mammographic study at time of interpretation, months sin

282 t time of interpretation, months since prior mammographic study, and compressed breast thickness.

283 Whether mammographic surveillance after BCS occurs and by whom i

284 Decisions on mammographic surveillance should also incorporate whethe

285 nnual interval is preferable for ipsilateral mammographic surveillance, allowing detection of a signi

286 roving the image quality of radiographic and mammographic systems while reducing patient dose.

287 rs were assigned to evaluate images from two mammographic systems.

288 d to evaluate image quality for all types of mammographic systems.

289 Mean mammographic target to reflector distance was 0.3 cm.

290 an increased risk of breast cancer and lower mammographic tumor detectability.

291 Average mammographic tumor size of missed cancers manifesting as

292 The median difference from baseline mammographic tumor size to surgery was 0 cm (8.6 cm smal

293 n density readings was similar regardless of mammographic types paired (67.3%-71.0%).

294 Purpose To review mammographic, ultrasonographic (US), and magnetic resona

295 Two radiologists reviewed the mammographic, US, and MR images.

296 ime without CAD increased with the number of mammographic views (P < .0001).

297 calcified lesions compared with supplemental mammographic views.

298 ith tomosynthesis and once with supplemental mammographic views; both modes included the mediolateral

299 of the early development of mammography and mammographic wire localizations.

300 The digital mammograms were displayed on mammographic workstations and printed on film according